Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Novartis: Bimagrumab/BYM338 Bimagrumab is an antibody against activin type II receptor (ActRII) meaning that it acts as an ActRII antagonist (It prevents ActRII from functioning)
Presented for research literature review only Banger KK et al
Evidence Builds The SURMOUNT-OSA trial, funded by Eli Lilly, added to this evidence
Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14
In addition, Ab#2_DSB#1 displayed equivalent terminal half-life in mice based on Fc detection and GLP-1R activity (Supplementary Table 4) with no significant loss of peptide activity for at least 7 days (Fig
US$ 21.27
US$ 23.02
US$ 23.34
US$ 21.72
US$ 25.95
US$ 26.05
